ADAG
Adagene Inc
$
1.750
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.850
Open
1.690
VWAP
1.78
Vol
47.90K
Mkt Cap
82.44M
Low
1.690
Amount
85.41K
EV/EBITDA(TTM)
--
Total Shares
44.16M
EV
15.46M
EV/OCF(TTM)
--
P/S(TTM)
954.46
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Show More
Valuation Metrics
The current forward P/E ratio for Adagene Inc (ADAG.O) is -2.11, compared to its 5-year average forward P/E of -3.39. For a more detailed relative valuation and DCF analysis to assess Adagene Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.39
Current PE
-2.11
Overvalued PE
-0.25
Undervalued PE
-6.53
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.45
Current EV/EBITDA
-0.38
Overvalued EV/EBITDA
1.90
Undervalued EV/EBITDA
-4.80
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
17.69
Current PS
8.85
Overvalued PS
44.88
Undervalued PS
-9.50
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
3.6M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ADAG News & Events
Events Timeline
2025-07-15 (ET)
2025-07-15
07:04:28
Adagene announces regulatory update on development plan for muzastotug
2025-07-08 (ET)
2025-07-08
07:09:02
Adagene and ConjugateBio partner to develop antibody drug conjugate
2025-07-01 (ET)
2025-07-01
07:07:24
Adagene announces up to $25M strategic investment from Sanofi
Sign Up For More Events
Sign Up For More Events
News
8.5
07-01NASDAQ.COMAdagene Announces Upto $25 Mln Investment From Sanofi, Stock Up In Pre-Market
1.0
05-27NewsfilterAdagene to Present at Jefferies Global Healthcare Conference 2025
8.5
04-21Investing.comAdani Group to invest additional $10 billion in Indian data centers - Bloomberg By Investing.com
Sign Up For More News
People Also Watch
METCB
Ramaco Resources Inc
13.950
USD
+6.41%
VTGN
Vistagen Therapeutics Inc
2.550
USD
+0.39%
BLUE
bluebird bio Inc
0
USD
0.00%
SKYE
Skye Bioscience Inc
3.890
USD
+4.57%
CNF
CNFinance Holdings Ltd
0.730
USD
-7.60%
DIT
Amcon Distributing Co
114.010
USD
+2.71%
AMTD
AMTD IDEA Group
1.030
USD
-3.74%
RGLS
Regulus Therapeutics Inc
0
USD
+0.25%
CBAT
CBAK Energy Technology Inc
1.110
USD
-1.77%
EDAP
Edap Tms SA
1.520
USD
-2.56%
FAQ
What is Adagene Inc (ADAG) stock price today?
The current price of ADAG is 1.75 USD — it has increased 3.55 % in the last trading day.
What is Adagene Inc (ADAG)'s business?
What is the price predicton of ADAG Stock?
What is Adagene Inc (ADAG)'s revenue for the last quarter?
What is Adagene Inc (ADAG)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Adagene Inc (ADAG)'s fundamentals?
How many employees does Adagene Inc (ADAG). have?